Modified free-living microbes, vaccine compositions and methods of use thereof
Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.
1. An isolated mutant Listeria monocytogenes strain comprising a genetic mutation in one or more genes selected from the group consisting of uvrA, uvrB, uvrC, uvrD, and phrB that attenuates its ability to repair its nucleic acid.
2. The mutant strain of claim 1 , which comprises a genetic mutation in the uvrA gene, the uvrB gene, or both the uvrA and uvrB genes.
3. The mutant strain of claim 1 , which comprises a defective UvrC enzyme.
4. The mutant strain of claim 1 , wherein the nucleic acid of the bacteria of the strain has been modified by reaction with a nucleic acid targeted compound that reacts directly with nucleic acid so that the bacteria are attenuated for proliferation.
5. The mutant strain of claim 1 , wherein the strain comprises a heterologous expression cassette comprising a polynucleotide sequence encoding an antigen wherein the sequence is codon-optimized for expression in the strain.
6. The mutant strain of claim 1 , wherein the strain comprises a heterologous expression cassette comprising a polynucleotide sequence encoding an antigen fused to a signal peptide wherein the sequence is codon-optimized for expression in the strain.
7. A vaccine comprising (a) the mutant strain of claim 1 , and (b) a pharmaceutically acceptable carrier or adjuvant.
8. The mutant strain of claim 1 , wherein the strain comprises a heterologous nucleic acid sequence encoding an antigen.
9. The mutant strain of claim 8 , wherein the antigen is a tumor antigen.
10. The mutant strain of claim 9 , wherein the tumor antigen is mesothelin, SPAS-1, proteinase-3, SP-17, gp100, PAGE-4, TARP, Her-2/neu, WT-1, NY-ESO-1, PSMA, K-ras or CEA, or an immunogenic fragment of mesothelin, SPAS-1, proteinase-3, SP-17, gp100, PAGE-4, TARP, Her-2/neu, WT-1, NY-ESO-1, PSMA, K-ras or CEA.
11. The mutant strain of claim 8 , wherein the antigen is an infectious disease antigen.
12. An isolated mutant Bacillus anthracis strain comprising a genetic mutation in one or more genes selected from the group consisting of uvrA, uvrB, uvrC, uvrD, and phrB that attenuates its ability to repair its nucleic acid.
13. The mutant strain of claim 12 , which comprises a genetic mutation in the uvrA gene, the uvrB gene, or both the uvrA and uvrB genes.
14. The mutant strain of claim 12 , which comprises a defective UvrC enzyme.
15. The mutant strain of claim 12 , which further comprises one or more mutations in the lef gene, the cya gene, or both genes that decreases the toxicity of the strain.
16. The mutant strain of claim 12 , wherein the nucleic acid of the bacteria of the strain has been modified by reaction with a nucleic acid targeted compound that reacts directly with nucleic acid so that the bacteria are attenuated for proliferation.